PTAB challenges

Proceedings overview

There is one active AIA trial proceeding on file for US12295968. This proceeding, PGR2026-00025, is currently in the "Pending" status, meaning no final decision has been reached regarding the patentability of its claims. As such, the patent claims remain legally intact, and the patent has not yet been hardened or invalidated by PTAB review.

PGR2026-00025 — Bicara Therapeutics, Inc. v. Atul Bedi et al

• Type: Post-Grant Review
• Filed: 2026-02-10
• Status: Pending. The petition has been filed, and the PTAB is currently reviewing it to determine whether to institute a trial.
• Judge panel: The judge panel information is not yet publicly available for this pending proceeding.
• Petition grounds: The specific claims challenged, prior art asserted, and statutory bases (§ 102 / § 103 / § 112) for this petition are not yet publicly available in the provided information or readily discoverable through general search at this early stage of the proceeding.
• Institution decision: Not yet issued. The institution decision is due approximately 6 months from the filing date, around August 10, 2026.
• Final Written Decision: Not applicable; the proceeding is pending.
• Settlement / termination: Not applicable; the proceeding is pending.
• Appeal: Not applicable; the proceeding is pending.
• Defensive value: This pending PGR indicates a challenge to the patent's validity. If the petition is instituted, it could lead to the cancellation of claims. Until then, the claims are presumed valid. A defendant facing assertion of this patent should monitor this proceeding closely, as its outcome will directly impact the strength of the patent.

Strategic summary

Currently, all claims of US12295968 are considered UNTESTED in the context of a final PTAB decision, as the sole pending Post-Grant Review (PGR2026-00025) has not yet reached an institution decision. There are no claims that have been definitively CANCELED or SUSTAINED by the PTAB.

The estoppel landscape is nascent. Since PGR2026-00025 is in its early stages, the full scope of prior-art grounds challenged by Bicara Therapeutics, Inc. is not yet public. Once an institution decision is made (if instituted), Bicara Therapeutics, Inc. (and its privies) would be estopped under § 315(e)(2) from asserting in future civil actions or ITC proceedings any grounds raised or that reasonably could have been raised in the PGR. For other potential defendants, the grounds in this pending PGR are still available for their own challenges if they are not in privity with Bicara Therapeutics, Inc. There is no public indication of multiple filings by the same petitioner or aggressive patent owner appeals at this stage. Unified Patents has publicly listed the PGR filing.

Recommended next steps

For a defendant facing assertion of US12295968:

• Monitor PGR2026-00025 closely: The key milestone to watch is the institution decision deadline, which is around 2026-08-10. The PTAB's decision to institute or deny the petition will significantly impact the patent's perceived strength. Details of the petition, including specific claims challenged and prior art, may become public upon institution. You can track this proceeding on the USPTO PTAB E2E system by searching for PGR2026-00025.
• Review the petition: Once publicly available (typically upon institution), thoroughly analyze the petition filed by Bicara Therapeutics, Inc. to understand the specific validity arguments and prior art being asserted against US12295968. This information is crucial for evaluating defensive strategies.
• No PTAB activity beyond this pending PGR: The absence of other PTAB proceedings on US12295968 means the patent has not yet undergone extensive inter partes review, which can make it appear less "hardened" than patents that have survived multiple challenges. This may suggest that a PTAB challenge could be a viable defensive option if your organization is not in privity with Bicara Therapeutics, Inc. and has strong prior art.